These findings confirm the prior consensus that positioned dupilumab as the optimal therapy for CRSwNP, and provide the first evidence indicating that tezepelumab achieves comparable efficacy to omalizumab in NPS reduction and symptom relief, suggesting its potential as a novel TSLP inhibitor alternative. Here, TSLP is linked to chronic rhinosinusitis with nasal polyps.